title: Modified administration schedule of docetaxel, cisplatin, and fluorouracil for advanced or recurrent gastric cancer with gastrointestinal stenosis.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF)in patients with advanced gastric cancer with gastrointestinal stenosis in clinical practice.
  
  
  METHODS
  In the chemotherapy-naïve patients who had metastatic or recurrent histologically confirmed gastric cancer, docetaxel(40mg/m2), levofolinate(200mg/m / / / 2), fluorouracil(400mg/m2)on day 1, fluorouracil 1,000 mg/m2d-2 days intravenous continuous in fusion beginning on day 1, and cisplatin(40mg/m2)on day 3 was administered every 2 weeks.
  
  
  RESULTS
  Six patients received mDCF therapy. In 5 patients with measurable disease, the overall response rate was 86%. Median progression-free survival was 310 days and median overall survival was 599 days. Symptom improvement after the first cycle of mDCF was obtained in all patients. Grade 3 or 4 leukopenia and neutropenia were observed in 2(33%)and 6(100%)patients, respectively. There were no treatment-related deaths.
  
  
  CONCLUSIONS
  mDCF seems to be active against metastatic and recurrent gastric cancer with gastrointestinal stenosis. Further study is needed to confirm the efficacy and safety of mDCF regimen.
authors.affiliation: Dept. of Medical Oncology, Akita Red Cross Hospital.
authors.forename: Osamu
authors.initials: O
authors.lastname: Muto
authors.forename: Toshiya
authors.initials: T
authors.lastname: Sawada
authors.forename: Kei
authors.initials: K
authors.lastname: Kotanagi
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Sato
authors.forename: Takuya
authors.initials: T
authors.lastname: Kichiraku
authors.forename: Wataru
authors.initials: W
authors.lastname: Iwasaki
authors.forename: Masaki
authors.initials: M
authors.lastname: Kikkawa
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ouchi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kotanagi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D017219:Gastric Outlet Obstruction / Q000209:etiology*; D005767:Gastrointestinal Diseases; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil